ANDA 210157, held by Rising. Oseltamivir Phosphate.
As of Nov 16, 2026, ANDA 210157 (Oseltamivir Phosphate), held by Rising, was first approved by FDA on Jan 21, 2021, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 21, 2021 | Original application | Approved | None posted |
| Oseltamivir PhosphateEQ 30MG BASE · capsule;oral | Oseltamivir Phosphate | Discontinued |
| Oseltamivir PhosphateEQ 45MG BASE · capsule;oral | Oseltamivir Phosphate | Discontinued |
| Oseltamivir PhosphateEQ 75MG BASE · capsule;oral | Oseltamivir Phosphate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters